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Peripheral primitive neuroectodermal tumors (pPNETs) of the ovary are rare monophasic teratomas, and
fewer than 100 cases have been reported in the literature. pPNETs mainly involve young women during
their reproductive age, therefore, accurate diagnosis followed by multimodal treatment should be taken
into consideration for fertility preservation. We report a patient with stage IA pPNET of the ovary
presenting with acute abdominal pain secondary to torsion that was successfully managed by fertility-
sparing surgery and six courses of combination chemotherapy with vincristine, Adriamycin, and
cyclophosphamide. She has had a disease-free survival of >3 years. This brief review demonstrates the
clinical course of pPNET and summarizes the literature to show that clinical stage at the time of diag-
nosis is the most important prognostic factor and that the vast majority of recurrences are observed
within 10 years.
Copyright  2013, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Clinical presentation
A 28-year-old woman, G0P0, presented with sudden onset of
lower abdominal pain. Prior to this, neither family history nor other
medical or surgical illnesses were remarkable. Past menstruation
history was regular. Physical examination revealed an acutely ill-
looking woman with a palpable ﬁrm and smooth-surfaced mass
without rebounding pain or muscle guarding. Further physical
examination showed a normal female pattern, without other pos-
itive ﬁndings, except the those mentioned above. Computed to-
mography (CT) demonstrated a 12-cm complex mass at the left
adnexa (Fig. 1). The tumor markers, including cancer antigen (CA)
125, CA 19-9, and a-fetoprotein, were all within normal limits.ics and Gynecology, Taipei
g@ym.edu.tw (P.-H. Wang).
ia-PaciﬁcAssociation forGynecologicEnExploratory laparotomy showed torsion of the left ovarian tumor
(Fig. 2). Left salpingo-oophorectomy was performed, and immedi-
ate frozen pathology favored a diagnosis of granulosa cell tumor,
based on the presence of small round cells with prominent necrosis
(Figs. 3 and 4). Fertility-preserving staging surgery then followed,
and included appendectomy, left pelvic lymph node dissection,
partial omentectomy, and peritoneal washing cytology. The patient
recovered well and was discharged from the hospital on post-
operative day 7.
Diagnosis and management
Immunohistochemistry was reactive for CD-99 (the glyco-
protein cluster of differentiation molecule 99 (MIC2)), Friend
leukemia virus integration (FLI)-1 and glial ﬁbrillary acidic
protein, and lacking for Melan A, a-inhibin, calretinin, cytoker-
atin, epithelial membrane antigen (EMA), synaptophysin, chro-
mogranin, myogenic regulatory factor 1 (myoD1), vimentin, and
desmin (Fig. 5). The ﬁnal pathology was peripheral primitivedoscopyandMinimally InvasiveTherapy.PublishedbyElsevierTaiwanLLC.All rights reserved.
Fig. 1. Pelvic computed tomography revealed a round-shaped heterogeneous mass,
with a solid and cystic multilobulated pattern, about 8.4 cm  11.2 cm  12.7 cm, in the
midline anterior pelvis, favoring a left ovarian tumor.
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Ewing sarcoma (ES) gene translocation was positive using the
Vysis EWS Dual Color Break Apart Probe: 30-190059 (Vysis,
Downer’s Grove, IL, USA).
Bone marrow examination showed a normal 46,XX karyotype
and there was no evidence of tumor involvement. The patient
received six courses of combination chemotherapy, including
vincristine, Adriamycin, and cyclophosphamide as adjuvant therapy,
without further radiotherapy. In the last follow-up at 3 years post-
operative, a series of examinations, including bone scan andpositron
emission tomography/CT, showed the patient was free of tumor.Discussion
pPNET, classiﬁed as part of the Ewing family of tumors (EFTs),
are a group of highly malignant tumors composed of small roundFig. 2. Left ovarian tumor with torsion was noted during the operation.cells of neuroectodermal origin that affect soft tissue and bone,
for the most part.1 The EFTs present a spectrum of neoplastic
diseases, which include undifferentiated ES, atypical poorly
differentiated ES, Askin tumor, and pPNET.2,3 Although there are
differences in tumor characteristics and clinical manifestations of
EFTs, they are known to share the same reciprocal balance
translocations, t(11,22)(q24;q12), which fuse the 50 portion of the
EWSR1 gene on chromosome 22 to the 30 portion of the FLI-1
gene on chromosome 11 in 85e90% of cases.4,5 The EFTs often
arose from the long bones of the extremities and pelvis, and 20e
30% of patients have a soft tissue origin.6
pPNET of the ovary is extremely rare, and is not considered a
common differential diagnosis of an ovarian tumor with torsion.
Preoperative CT imaging and magnetic resonance imaging are
nonspeciﬁc and variable.7 With regard to the clinicopathological
features of the reported cases of pPNET of the ovary, all the pa-
tients were young (13e29 years, mean: 23.5 years) (Table 1).8e12
pPNET of the ovary in some reported cases was associated with
teratomas, and the cases were therefore considered to be PNETs of
the central nervous system arising as components of such
teratomas.13,14
In our case, initial frozen pathology revealed small round cells
with prominent necrosis, suggesting a diagnosis of granulosa cell
tumor.15 The permanent histological report was pPNET of the
ovary, and this was validated by immunostaining, reverse tran-
scriptase polymerase chain reaction, and karyotyping. The dif-
ferential diagnosis of small round cell tumors of the ovary
includes pPNET/ES, granulosa cell tumor, small cell tumor of a
hypercalcemic type, and intra-abdominal desmoplastic small cell
tumor.16
Immunohistochemistry can be used to detect FLI-1 in the gene
fusion product of pPNET/ES. The expression of the MIC2 gene
produces an antigen, MIC2, which consistently identiﬁes both ES
and pPNETs. By contrast, central nervous system PNETs and neu-
roblastomas uniformly lack expression of MIC2. Furthermore,
pPNETs typically coexpress CD99 and vimentin. Other nonspeciﬁc
markers include S-100, neuron-speciﬁc enolase, CD75, and syn-
aptophysin.9,17 Granulosa cell tumors are constantly positive with
a-inhibin and calretinin and partially reactive with CD56, CD99,
CD2-40, and low-molecular-weight keratin. Melan-A, CD10, and
EMA are negative.18
Ovarian small cell carcinomas of the hypercalcemic type are
positive for EMA, cytokeratin antibodies, N terminus of Wilms’
tumor suppressor protein 1 (WT1), calretinin, and CD1. Para-
thyroid hormone-related protein is partially reactive and may be
the explanation for the hypercalcemia in these cases. Desmin,
S100, and a-inhibin are constantly negative.16 Ovarian small cell
tumors of a pulmonary type are positive for cytokeratin anti-
bodies, EMA, and neuroendocrine markers.19
Intra-abdominal desmoplastic small round cell tumors are
characterized by immunoreactivity with a variety of epithelial
neural and mesenchymal markers. Desmin positivity is espe-
cially common, usually with a globular paranuclear pattern, and
many cases exhibit nuclear positivity with the C terminus of
WT1, in contrast to ovarian small cell tumors of the hypercal-
cemic type, which exhibit nuclear positivity with antibodies
against the N terminus. Intra-abdominal desmoplastic small
round cell tumors are usually positive for cytokeratin antibodies;
other markers that are commonly positive include EMA,
vimentin, neuron-speciﬁc enolase, CD57 (B3GAT1 (CD57) beta-
1,3-glucuronyltransferase 1 (glucuronosyltransferase P), CD15
(FUT4 (CD15) fucosyltransferase 4 (alpha (1,3) fucosyltransfer-
ase, myeloid-speciﬁc), MOC-31 (a cell-membrane glycoprotein
present on the surface of epithelial cells), and Ber-EP4 (a Mr
34,000 human epithelium-speciﬁc surface glycoprotein: a
Table 1
Peripheral primitive neuroectodermal tumor of the ovary.
Authors Age
(y)
FIGO stage Treatment C/T regimen Complications Follow-up
Kawauchi et al9 29 IIa TAH þ BSO þ omentectomy þ PALA
C/T
NDAb NDA 11 mo
DOD
Chow et al10 13 IV Debulking
C/T
2nd debulking surgery
C/T þ R/T
BEP
VIP
EPDC
NDA 17 mo
DOD
Demirtas et al8,c 25 IC LSO þ omentectomy þ PLA
2nd look laparotomy
BEP
VIP
Pelvic abscess after 2nd look
laparotomy þ VIP
2 y
NED
2 successive
pregnancies
Kim et al11 18 IIIC RSO þ omentectomy þ PLA þ PALA
R/T
TP
VACA
Bowel obstruction 10 mo
DOD
Ateser et al12 28 IV TAH þ LSO þ omentectomy
R/T
VDC at GA 30 wk
DAC
EIP
Neutropenia, placental
metastasis
13 mo
DOD
Huang et ald 28 IA LSO þ omentectomy þ left PLA þ
appendectomy)
VDC 28 mo
NED
A ¼ actinomycin-D; B ¼ bleomycin; BEP ¼ bleomycin, etoposide, cisplatin; BSO ¼ bilateral salpingo-oophorectomy; C ¼ cyclophosphamide; C/T ¼ chemotherapy;
D ¼ doxorubicin; DAC ¼ doxorubicin, cyclophosphamide, docetaxel; DOD ¼ died of disease; E ¼ etoposide; EIP ¼ ifosfamide, vinblastine, cisplatinum; EPDC ¼ etoposide,
cisplatin, doxorubicin, cyclophosphamide; FIGO¼ International Federation of Obstetrics and Gynecology; GA¼ gestational age; I¼ ifosfamide; IC¼ in FIGO stage IC; LSO¼ left
salpingo-oophorectomy; NDA ¼ no data available; NED ¼ no evidence of disease; P ¼ cisplatin; PALA ¼ para-aortic lymphadenectomy; PLA ¼ pelvic lymphadenectomy;
RSO ¼ right salpingo-oophorectomy; R/T ¼ radiotherapy; T ¼ paclitaxel; TAH ¼ total abdominal hysterectomy; TP ¼ paclitaxel, cisplatin; V ¼ vinblastine; VACA ¼ vincristine,
actinomycin, cyclophosphamide, doxorubicin; VDC ¼ vincristine, doxorubicin, cyclophosphamide; VIP ¼ vincristine, ifosfamide, cisplatin.
a Tumor nodules on pelvic ﬂoor.
b Regimens for common ovarian carcinoma, malignant germ cell tumor, or small cell carcinoma.
c No available immunostaining or karyotype report.
d Current case: ovarian tumor with torsion.
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covalently linked glycopolypeptides expressed by most human
epithelial cells and carcinomas).20
In addition to their cytogenetic and immunohistochemical simi-
larities, the pPNET/ESs share important clinical features and should
be treated similarly.21 Fewer than 25% of patients have overt
metastasis at the time of diagnosis, therefore, the relapse rate could
be 80e90% inpatients undergoing local therapyalone. It is suggested
that the majority of patients have subclinical metastatic disease at
the time of diagnosis, even in the absence of overt metastases.
pPNET/ESs are characterized by rapid growth and a high po-
tential to recur, most commonly in the lungs, bones, and bone
marrow.22 Despite multimodal treatment involving surgery,
chemotherapy, or radiotherapy, patients with advanced disease
show rapid dissemination (Table 1). Out of concern for the future
fertility of our patient, fertility-sparing surgery was performed and
adjuvant chemotherapy given, which has been accepted in theFig. 3. The ovarian tumor was well demarcated and well encapsulated. The cut surface
was solid with focal necrosis, hemorrhage, and cystic change.management of many kinds of gynecological tract neoplasms and
cancers.23e26 Demirtas et al8 have reported a patient that had two
successive pregnancies after treatment of International Federation
of Obstetrics andGynecology (FIGO) stage IC pPNETof the ovary; the
patient’s reproductive functionwas preserved after fertility-sparing
surgery and adjuvant chemotherapy. However, the follow-up time
after treatment in these patients is short (only 2e3 years), including
our current patient; therefore, the feasibility of fertility-sparing
surgery in these pPNET/ES survivors needs conﬁrmation, because
this situation is similar to other conservative treatment for other
gynecological tract cancers.24,27 Current standard chemotherapy for
nonmetastatic pPNET/ES includes vincristine, doxorubicin, and
cyclophosphamide alternating with ifosfamide and etoposide.28
Some chemotherapeutic agents, including trabectedin (ecteinasci-
din 743, or ET-743) and palifosfamide (ZIO-201) for the treatment of
sarcoma29 might also be useful in cases of pPNET/ES; especially for
those patients who have failed or are not candidates for
anthracycline-based or ifosfamide-based chemotherapy.30 Tra-
bectedin, a chemotherapeutic agent originally derived from a ma-
rine tunicate, binds to the minor groove of DNA affecting
transcription and inducing the formation of DNA double-strand
breaks, and cells in the G1 phase of the cell cycle are particularly
sensitive to trabectedin.29 Trabectedin is generally well tolerated,
but some patients after treatment may develop severe myelosup-
pression, with prolonged and severe neutropenia and thrombocy-
topenia, and hepatic toxicity.29 Palifosfamide is a stabilized
formation of isophosphoramide mustard (the active metabolite of
ifosfamide) that appears to be active in sarcomas and better toler-
ated than ifosfamide, because palifosfamide has antitumor activity
comparable or superior to that of ifosfamide, and does not display
the nephrotoxic effects associated with ifosfamide.31
Adjuvant radiotherapy is indicated for patients undergoing sur-
gery if the surgical margins are inadequate, although effective
chemotherapy also reduces the risk of local failure in such patients.32
Although the majority of pPNET/ES survivors have some late
effects of therapy, in terms of employment, marital status,
fertility, and functional status, secondary myelodysplasia and
Fig. 5. Immunohistochemical staining. Positive glial ﬁbrillary acidic protein expression revealed more differentiation from small primitive cells. Positive CD-99 (MIC-2) was
expressed in the cytoplasm. Friend leukemia integration (FLI)-1 is expressed within the nuclei of the tumor cells. EWS gene translocation was demonstrated by ﬂuorescence in situ
hybridization, but not frequently.
Fig. 4. Tumor cells grew in a solid sheet patternwith intervening edematous stroma and showed vascular invasion and focal necrosis (AeC). Tumor cells were small, round and with
less cytoplasm with indistinct cell boundaries; rosettoid features are present (D). (A, 100; B and C, 200; D, 400; hematoxylin and eosin stain).
B.-S. Huang et al. / Gynecology and Minimally Invasive Therapy 2 (2013) 65e6968acute myeloblastic leukemia occur in only 1e2% of survivors.33,34
Furthermore, Kuttesch et al35 have reported that 20% of patients
who received radiotherapy doses >60 Gy developed secondary
malignancies, compared with only 5% of those who received 48e
60 Gy. Those treated with <48 Gy had no additional risk of sec-
ond malignancies. Although the appropriate duration of follow-
up is unknown, the vast majority of recurrences are observed
within 10 years. It is suggested that positron emissiontomography/CT may have great utility in monitoring the response
to chemotherapy and/or radiotherapy, and in the postoperative
evaluation of recurrence.36
Acknowledgments
This work was supported in part by grants from Taipei Veterans
General Hospital (V99C1-085, V100C-054, V101C1-128, V101E4-
B.-S. Huang et al. / Gynecology and Minimally Invasive Therapy 2 (2013) 65e69 69004, V101E5-006), the TVGH-NTUH Joint Research Program
(96VN-008, 97VN-012, 98VN-015), Veterans General Hospitals
University System of Taiwan Joint Research Program (VGHUST99-
G4), and the National Science Council (NSC 99-2314-B-010-009-
MY3), Taiwan.
References
1. Grier HE. The Ewing family of tumors. Ewing’s sarcoma and primitive neuro-
ectodermal tumors. Ped Clin North Am. 1997;44:991e1004.
2. Askin FB, Rosai J, Sibley RK, Dehner LP, McAlister WH. Malignant small cell
tumor of the thoracopulmonary region in childhood: a distinctive clinico-
pathologic entity of uncertain histogenesis. Cancer. 1979;43:2438e2451.
3. Dehner LP. Primitive neuroectodermal tumor and Ewing’s sarcoma. Am J Surg
Pathol. 1993;17:1e13.
4. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding
domain caused by chromosome translocation in human tumours. Nature.
1992;359:162e165.
5. Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the
Ewing’s sarcoma and peripheral neuroepithelioma t(11;22) translocation
breakpoints. Genes Chromosomes Cancer. 1992;5:271e277.
6. Applebaum MA, Worch J, Matthay KK, et al. Clinical features and outcomes in
patients with extraskeletal Ewing sarcoma. Cancer. 2011;117:3027e3032.
7. Li X, Zhang W, Song T, Sun C, Shen Y. Primitive neuroectodermal tumor arising
in the abdominopelvic region: CT features and pathology characteristics. Abd
Imag. 2011;36:590e595.
8. Demirtas E, Guven S, Guven ES, Baykal C, Ayhan A. Two successful spontaneous
pregnancies in a patient with a primary primitive neuroectodermal tumor of
the ovary. Fertil Steril. 2004;81:679e681.
9. Kawauchi S, Fukuda T, Miyamoto S, et al. Peripheral primitive neuroectodermal
tumor of the ovary conﬁrmed by CD99 immunostaining, karyotypic analysis,
and RT-PCR for EWS/FLI-1 chimeric mRNA. Am J Surg Pathol. 1998;22:1417e
1422.
10. Chow SN, Lin MC, Shen J, Wang S, Jong YJ, Chien CH. Analysis of chromo-
some abnormalities by comparative genomic hybridization in malignant
peripheral primitive neuroectodermal tumor of the ovary. Gynecol Oncol.
2004;92:752e760.
11. Kim KJ, Jang BW, Lee SK, Kim BK, Nam SL. A case of peripheral primitive
neuroectodermal tumor of the ovary. Int J Gynaecol Cancer. 2004;14:370e372.
12. Ateser G, Yildiz O, Leblebici C, et al. Metastatic primitive neuroectodermal
tumor of the ovary in pregnancy. Int J Gynaecol Cancer. 2007;17:266e269.
13. Dehner LP. Peripheral and central primitive neuroectodermal tumors. A noso-
logic concept seeking a consensus. Arch Path Lab Med. 1986;110:997e1005.
14. Kleinman GM, Young RH, Scully RE. Primary neuroectodermal tumors of the
ovary. A report of 25 cases. Am J Surg Pathol. 1993;17:764e778.
15. Lee WL, Yuan CC, Lai CR, Wang PH. Hemoperitoneum is an initial presen-
tation of recurrent granulosa cell tumors of the ovary. Jpn J Clin Oncol.
1999;29:509e512.
16. McCluggage WG, Oliva E, Connolly LE, McBride HA, Young RH. An immuno-
histochemical analysis of ovarian small cell carcinoma of hypercalcemic type.
Int J Gynecol Pathol. 2004;23:330e336.
17. Folpe AL, Hill CE, Parham DM, O’Shea PA, Weiss SW. Immunohistochemical
detection of FLI-1 protein expression: a study of 132 round cell tumors withemphasis on CD99-positive mimics of Ewing’s sarcoma/primitive neuro-
ectodermal tumor. Am J Surg Pathol. 2000;24:1657e1662.
18. Nofech-Mozes S, Ismiil N, Dube V, et al. Immunohistochemical characterization
of primary and recurrent adult granulosa cell tumors. Int J Gynecol Pathol.
2012;31:80e90.
19. Eichhorn JH, Young RH, Scully RE. Primary ovarian small cell carcinoma of
pulmonary type. A clinicopathologic, immunohistologic, and ﬂow cytometric
analysis of 11 cases. Am J Surg Pathol. 1992;16:926e938.
20. Ordonez NG. Desmoplastic small round cell tumor: II: an ultrastructural and
immunohistochemical study with emphasis on new immunohistochemical
markers. Am J Surg Pathol. 1998;22:1314e1327.
21. Castex MP, Rubie H, Stevens MC, et al. Extraosseous localized ewing tumors:
improved outcome with anthracyclines e the French society of pediatric
oncology and international society of pediatric oncology. J Clin Oncol. 2007;25:
1176e1182.
22. Iwamoto Y. Diagnosis and treatment of Ewing’s sarcoma. Jpn J Clin Oncol.
2007;37:79e89.
23. Chang YW, Chao KC, Sung PL, Li WH, Wang PH. Fertility preservation with
treatment of endodermal sinus tumor of the ovary. J Chin Med Assoc. 2013;76:
112e114.
24. Lee WL, Lee FK, Su WH, et al. Hormone therapy for younger patients with
endometrial cancer. Taiwan J Obstet Gynecol. 2012;51:495e505.
25. Huang BS, Seow KM, Tsui KH, Huang CY, Lu YF, Wang PH. Fertility outcome of
infertile women with adenomyosis treated with the combination of a con-
servative microsurgical technique and GnRH-agonist: long-term follow-up in a
series of nine patients. Taiwan J Obstet Gynecol. 2012;51:212e216.
26. Tsui KH, Wang PH. Borderline ovarian tumor and future fertility. J Chin Med
Assoc. 2011;74:241e242.
27. Wang PH, Horng HC, Chen YJ. Is it possible to use laparoscopy to ﬁnish cys-
tectomy for big ovarian cysts? Gynecol Minimal Invas Ther. 2013;2:1e2.
28. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to
standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal
tumor of bone. New Engl J Med. 2003;348:694e701.
29. D’Adamo DR. Appraising the current role of chemotherapy for the treatment of
sarcoma. Semin Oncol. 2011;38:S19eS29.
30. Casali PG, Sanﬁlippo R, D’Incalci G. Trabectedin therapy for sarcomas. Curr Opin
Oncol. 2010;22:342e346.
31. Jung S, Kasper B. Palifosfamide, a bifunctional alkylator for the treatment of
sarcoma. IDrug. 2012;13:38e48.
32. Nesbit Jr ME, Gehan EA, Burgert Jr EO, et al. Multimodal therapy for the
management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term
follow-up of the First Intergroup study. J Clin Oncol. 1990;8:1664e1674.
33. Novakovic B, Fears TR, Horowitz ME, Tucker MA, Wexler LH. Late effects of
therapy in survivors of Ewing’s sarcoma family tumors. J Ped Hematol Oncol.
1997;19:220e225.
34. Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute
myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tu-
mor of bone: a report from the Children’s Oncology Group. Blood. 2007;109:
46e51.
35. Kuttesch Jr JF, Wexler LH, Marcus RB, et al. Second malignancies after Ewing’s
sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol.
1996;14:2818e2825.
36. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose posi-
tron emission tomography predicts outcome for Ewing sarcoma family of tu-
mors. J Clin Oncol. 2005;23:8828e8834.
